Bajaj Healthcare rises after CDMO pact for 15 new Active Pharma Ingredients

 Bajaj Healthcare saw a significant rise in its stock price after announcing a contract development and manufacturing organization (CDMO) agreement with UK and EU-based clients. The company has committed to supply 15 Active Pharmaceutical Ingredients (APIs) under this deal. These APIs, which include off-patent generics and some soon-to-be off-patent molecules, will be developed and manufactured exclusively for its clients at Bajaj's facility in Savli, Vadodara, Gujarat. Following the announcement, Bajaj Healthcare's stock surged by over 11%, reflecting investor optimism about the potential growth of the company and its expanded role in the global pharmaceutical supply chain




Comments

Popular posts from this blog

How To Travel With Student Loan Debt

Discover the Benefits of Owning a Corner Sofa

Apple is doubling down on India... because of Trump?